Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2451 to 2460 of 2683 total matches.
Simethicone for Gastrointestinal gas
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996 (Issue 977)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Gastrointestinal gas may cause symptoms when excessive amounts become trapped in the stomach and intestinal tract. Simethicone (Gas-X, Maalox Anti-Gas, Mylanta Gas Relief, Mylicon, Phazyme), sold over-the-counter in capsules, tablets and infant drop formulations, is being heavily advertised to the public for symptomatic treatment of flatulence and gastric bloating. According to a recent press release, 'Phazyme works fast so people can continue living active lives and eating the foods they love without fear of embarrassment.' Products that combine one or more antacids with simethicone...
Zinc for the Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997 (Issue 993)
resulting from any error, inaccuracy or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1 ...
Results of a recent study suggested that zinc gluconate may be effective in treating the common cold (SB Mossad et al, Ann Intern Med, 125:81, July 15, 1996). Zinc gluconate lozenges, sometimes combined with vitamin C or other ingredients, are available in pharmacies and health food stores throughout the USA.
Glucosamine for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Sep 26, 1997 (Issue 1010)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
The Medical Letter has received many inquiries about use of glucosamine, a basic constituent of articular cartilage glycosaminoglycans, for treatment of arthritis. A recently published book (The Arthritis Cure), several television news shows, and articles in The New York Times have suggested it may be effective for treatment of osteoarthritis. Glucosamine is sold as a 'dietary supplement' in the USA.
Raloxifene for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Mar 13, 1998 (Issue 1022)
.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com
The Medical Letter, Vol ...
Raloxifene (Evista - Lilly), a benzothiophene that acts on estrogen receptors, has recently been marketed for prevention of postmenopausal osteoporosis. Only estrogen (alone or in combination with a progestin) and the bisphosphonate alendronate (Fosamax) were previously approved by the FDA for this indication.
Prosorba Column for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com
The Medical Letter, Vol ...
Prosorba, an antibody-adsorbing column used with plasmapheresis, has been approved by the FDA for treatment of moderate-to-severe rheumatoid arthritis in patients refractory or intolerant to methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs).
In Brief: Plan B OTC
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
the pregnancy
rate to 1%, compared to an expected rate of 8% (Task
Force on Postovulatory Methods of Fertility ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
In Brief: Influenza Developments
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008 (Issue 1282)
Publication
IN BRIEF
Influenza Developments
Recent reports (D Kaye. Clin Infect Dis April 1, 2008;
46:iii ...
Recent reports (D Kaye.Clin Infect Dis April 1, 2008;46:iii) indicate that 2 of the 3 components of this year's influenza vaccine (Med Lett Drugs Ther 2007;49:81), the influenza B and A/H3N2 antigens, do not matchup well with circulating strains. The B component is probably not protective. The A/H3N2 antigen in the vaccine probably provides some protection, particularly for high-risk patients. The third component, the A/H1N1 antigen, is protective against circulating A/H1N1 influenza viruses, but these viruses, unlike previous A/H1N1 strains, are developing some resistance to oseltamivir...
Extended-Release Hydromorphone (Exalgo) for Pain
The Medical Letter on Drugs and Therapeutics • Aug 08, 2011 (Issue 1370)
-dumping”).1
PHARMACOLOGY — Hydromorphone has no analgesic
ceiling, but dosage is usually limited by its ...
The FDA has approved the opioid agonist hydromorphone in a once-daily extended-release (ER) oral tablet formulation (Exalgo – Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, long-term therapy. Another hydromorphone ER formulation (Palladone – Purdue) was available previously, but was withdrawn from the market because taking it with alcohol could interfere with the extended-release mechanism and lead to rapid release of potentially lethal amounts of the drug ("dose-dumping").
Dichlorphenamide (Keveyis) for Periodic Paralysis
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
%) benefited
from acetazolamide therapy.1
MECHANISM OF ACTION — Carbonic anhydrase
inhibitors are thought ...
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related variants.
Dichlorphenamide is the first drug to be approved in
the US for this indication. It was approved as Daranide
in 1958 for treatment of glaucoma, but had not been
marketed since 2002.
Ashwagandha Supplements
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
, and various cancers.1
AVAILABILITY — Ashwagandha is available commercially
in tablets, capsules, liquid ...
Ashwagandha is an herb extracted from the roots of
an evergreen shrub (Withania somnifera) found in
India that has been used as a "tonic" for centuries.
No specific constituent has been identified as an
active ingredient. Herbal supplements containing
ashwagandha, which is also known as winter cherry
and Indian ginseng, are widely promoted now in the
US for treatment of pain, anxiety, stress, fatigue, sleep
disturbances, cognitive decline, diabetes, arthritis,
male infertility, and various cancers.
